Balchem Corporation Reports First Quarter 2024 Financial Results
Balchem (NASDAQ: BCPC) reported record net sales of $239.7 million, net earnings of $29.0 million, adjusted EBITDA of $60.9 million, and free cash flow of $26.8 million for the first quarter of 2024. The Human Nutrition & Health segment saw significant growth, with sales up 15.1% and earnings up 80.4% compared to the prior year. The Animal Nutrition & Health segment experienced a decrease in sales, while the Specialty Products segment remained stable. The company's strong financial performance and sustainability initiatives signal a positive outlook for 2024.
Balchem reported record net sales of $239.7 million for the first quarter of 2024, marking a 3.1% increase from the prior year.
The company achieved record adjusted EBITDA of $60.9 million, up by 8.0% compared to the prior year quarter.
The Human Nutrition & Health segment recorded all-time high sales of $152.7 million, a 15.1% increase from the prior year, with earnings up 80.4%.
Balchem's strong financial performance in the first quarter, with net earnings of $29.0 million, signals a positive start to the year.
The company's Sustainability Report highlights its commitment to corporate social responsibility and sustainability goals for reducing greenhouse gas emissions and water usage by 25% by 2030.
The Animal Nutrition & Health segment experienced a decrease in sales of $11.0 million, down by 16.9% compared to the prior year quarter.
Earnings from operations for the Animal Nutrition & Health segment decreased by 78.3% in the first quarter of 2024.
The Specialty Products segment saw a slight decrease in quarterly sales of $0.6 million, down by 1.9% compared to the prior year quarter.
Operating expenses increased to $39.8 million for the quarter, primarily due to higher compensation-related expenses and other factors.
Despite overall positive performance, challenges in the Animal Nutrition & Health segment indicate areas for improvement in the company's diversified portfolio.
Insights
MONTVALE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2024 fiscal first quarter ended March 31, 2024. The Company reported quarterly net sales of
Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was a very good start to the year for Balchem. We delivered record net sales, adjusted EBITDA, and net earnings, as well as solid first quarter cash flows, despite the continued challenging environment in parts of our portfolio.”
First Quarter 2024 Financial Highlights:
- Net sales were a record
$239.7 million , an increase of3.1% compared to the prior year quarter. - Adjusted EBITDA was a record
$60.9 million , an increase of8.0% from the prior year quarter. - GAAP net earnings were
$29.0 million , an increase of27.6% from the prior year quarter. - GAAP earnings per share of
$0.89 compared to$0.70 in the prior year quarter and adjusted earnings per share(a) of$1.03 compared to$0.94 in the prior year quarter. - Cash flows from operations were
$33.4 million for the first quarter of 2024, with quarterly free cash flow(a) of$26.8 million . - Record Human Nutrition & Health segment sales of
$152.7 million , an increase of15.1% compared to the prior year quarter with record earnings from operations of$33.3 million , up80.4% .
Recent Highlights:
- On April 22, we released our 2023 Sustainability Report, highlighting the Company's Corporate Social Responsibility initiatives and accomplishments. Guided by our core values and our vision of making the world a healthier place, our Sustainability Report demonstrates both the Company's commitment to our corporate social responsibilities and our continued promise to provide our employees, customers, shareholders and the communities within which we operate with important information on our various initiatives.
- VitaCholine®, Balchem's market leading brand of the essential nutrient choline, has become a Proud Partner of the New York Jets, a major professional NFL sports team. This is the first sponsorship for VitaCholine® and the first sponsorship in the Nutritional Ingredient category for the Jets. The partnership will help VitaCholine® reach a large and health-conscious audience and promote its message of improving well-being of body and mind. VitaCholine® is a nutrient that supports both mental and physical performance by enhancing memory, accuracy and muscle control.
Mr. Harris said, "I am very pleased with the progress Balchem continues to make in advancing our sustainability efforts, as detailed in our 2023 Sustainability Report. Our performance, notably on our 2030 goals to reduce both greenhouse gas emissions and water usage by 25 percent, shows our commitment to our two main objectives: providing innovative solutions for the health and nutritional needs of the world and operating with excellence as strong stewards of our people, communities, and shareholders."
Mr. Harris continued, "I am excited about 2024. We had a very good start to the year financially and we continue to make good progress on our strategic initiatives that will support our growth over the longer term."
Results for Period Ended March 31, 2024 (unaudited)
(Dollars in thousands, except per share data)
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Net sales | $ | 239,659 | $ | 232,540 | ||
| Gross margin | 81,514 | 73,170 | ||||
| Operating expenses | 39,838 | 38,762 | ||||
| Earnings from operations | 41,676 | 34,408 | ||||
| Interest and other expenses | 4,826 | 5,289 | ||||
| Earnings before income tax expense | 36,850 | 29,119 | ||||
| Income tax expense | 7,864 | 6,409 | ||||
| Net earnings | $ | 28,986 | $ | 22,710 | ||
| Diluted net earnings per common share | $ | 0.89 | $ | 0.70 | ||
| Adjusted EBITDA(a) | $ | 60,866 | $ | 56,357 | ||
| Adjusted net earnings(a) | $ | 33,584 | $ | 30,581 | ||
| Adjusted net earnings per common share(a) | $ | 1.03 | $ | 0.94 | ||
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,627 | 32,415 | ||||
| (a) | See “Non-GAAP Financial Information” for a reconciliations of GAAP and non-GAAP financial measures. |
Financial Results for the First Quarter of 2024:
The Human Nutrition & Health segment generated record sales of
The Animal Nutrition & Health segment generated quarterly sales of
The Specialty Products segment generated quarterly sales of
Record quarterly consolidated gross margin of
Interest expense was
First quarter cash flows provided by operating activities were
Ted Harris said, “The Balchem team delivered record first quarter sales and adjusted EBITDA results, once again highlighting the resilience of our business model. Two of our three reporting segments are performing very well, with our Human Nutrition and Health segment delivering all-time record results which are more than offsetting the challenges we are experiencing in our Animal Nutrition and Health segment. We are well positioned in the markets we serve and remain confident in the long-term growth outlook for our markets as we continue to focus on progressing our strategic growth initiatives in 2024 and beyond.”
Quarterly Conference Call
A quarterly conference call will be held on Friday, May 3, 2024, at 11:00 AM Eastern Time (ET) to review first quarter 2024 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay three hours after the conclusion of the call through end of day Friday, May 17, 2024. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID #13745950.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," “likely,” "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this release. Factors that might cause differences from the forward-looking statements include those referred to or identified in Balchem’s Annual Report on Form 10-K for the year ended December 31, 2023 and other factors that may be identified elsewhere in this release or in our other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Jacqueline Yarmolowicz
Balchem Corporation
(Telephone: 845-326-5600)
Selected Financial Data (unaudited)
($ in 000’s)
| Business Segment Net Sales: | Three Months Ended March 31, | |||||
| 2024 | 2023 | |||||
| Human Nutrition & Health | $ | 152,744 | $ | 132,653 | ||
| Animal Nutrition & Health | 53,921 | 64,889 | ||||
| Specialty Products | 31,613 | 32,231 | ||||
| Other and Unallocated (b) | 1,381 | 2,767 | ||||
| Total | $ | 239,659 | $ | 232,540 | ||
| Business Segment Earnings Before Income Taxes: | Three Months Ended March 31, | |||||||
| 2024 | 2023 | |||||||
| Human Nutrition & Health | $ | 33,257 | $ | 18,435 | ||||
| Animal Nutrition & Health | 2,060 | 9,498 | ||||||
| Specialty Products | 8,199 | 7,946 | ||||||
| Other and Unallocated (b) | (1,840 | ) | (1,471 | ) | ||||
| Interest and other expenses | (4,826 | ) | (5,289 | ) | ||||
| Total | $ | 36,850 | $ | 29,119 | ||||
| (b) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs of | ||||||||
| Selected Balance Sheet Items | ||||||
| (Dollars in thousands) | March 31, 2024 | December 31, 2023 | ||||
| (unaudited) | ||||||
| Cash and Cash Equivalents | $ | 60,349 | $ | 64,447 | ||
| Accounts Receivable, net | 139,881 | 125,284 | ||||
| Inventories | 110,381 | 109,521 | ||||
| Other Current Assets | 14,248 | 14,990 | ||||
| Total Current Assets | 324,859 | 314,242 | ||||
| Property, Plant & Equipment, net | 274,033 | 276,039 | ||||
| Goodwill | 771,538 | 778,907 | ||||
| Intangible Assets with Finite Lives, net | 182,044 | 191,212 | ||||
| Right of Use Assets | 19,010 | 19,864 | ||||
| Other Assets | 17,216 | 16,947 | ||||
| Total Non-current Assets | 1,263,841 | 1,282,969 | ||||
| Total Assets | $ | 1,588,700 | $ | 1,597,211 | ||
| Current Liabilities | $ | 124,425 | $ | 148,491 | ||
| Revolving Loan | 301,569 | 309,569 | ||||
| Deferred Income Taxes | 51,006 | 52,046 | ||||
| Other Long-Term Obligations | 32,909 | 33,121 | ||||
| Total Liabilities | 509,909 | 543,227 | ||||
| Stockholders' Equity | 1,078,791 | 1,053,984 | ||||
| Total Liabilities and Stockholders' Equity | $ | 1,588,700 | $ | 1,597,211 | ||
Balchem Corporation
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 28,986 | $ | 22,710 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 13,668 | 13,646 | ||||||
| Stock compensation expense | 4,750 | 4,770 | ||||||
| Other adjustments | (949 | ) | 111 | |||||
| Changes in assets and liabilities | (13,067 | ) | (6,399 | ) | ||||
| Net cash provided by operating activities | 33,388 | 34,838 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures and intangible assets acquired | (6,910 | ) | (9,664 | ) | ||||
| Cash paid for acquisitions, net of cash acquired | — | (341 | ) | |||||
| Proceeds from the sale of assets | 213 | — | ||||||
| Investment in affiliates | (42 | ) | (56 | ) | ||||
| Net cash used in investing activities | (6,739 | ) | (10,061 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from revolving loan | 26,000 | 13,000 | ||||||
| Principal payments on revolving loan | (34,000 | ) | (22,000 | ) | ||||
| Principal payments on finance lease | (57 | ) | (55 | ) | ||||
| Proceeds from stock options exercised | 8,791 | 2,453 | ||||||
| Dividends paid | (25,555 | ) | (22,867 | ) | ||||
| Purchase of common stock | (5,202 | ) | (3,849 | ) | ||||
| Net cash used in financing activities | (30,023 | ) | (33,318 | ) | ||||
| Effect of exchange rate changes on cash | (724 | ) | 2,180 | |||||
| Decrease in cash and cash equivalents | (4,098 | ) | (6,361 | ) | ||||
| Cash and cash equivalents, beginning of period | 64,447 | 66,560 | ||||||
| Cash and cash equivalents, end of period | $ | 60,349 | $ | 60,199 | ||||
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Table 1
Reconciliation of Non-GAAP Measures to GAAP
(Dollars in thousands, except per share data)
(unaudited)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Reconciliation of adjusted gross margin | ||||||||
| GAAP gross margin | $ | 81,514 | $ | 73,170 | ||||
| Inventory valuation adjustment (1) | — | 1,202 | ||||||
| Amortization of intangible assets and finance lease (2) | 704 | 681 | ||||||
| Adjusted gross margin | $ | 82,218 | $ | 75,053 | ||||
| Reconciliation of adjusted earnings from operations | ||||||||
| GAAP earnings from operations | $ | 41,676 | $ | 34,408 | ||||
| Inventory valuation adjustment (1) | — | 1,202 | ||||||
| Amortization of intangible assets and finance lease (2) | 6,402 | 7,350 | ||||||
| Transaction and integration costs (3) | 440 | 2,165 | ||||||
| Nonqualified deferred compensation plan expense (4) | 403 | 237 | ||||||
| Adjusted earnings from operations | $ | 48,921 | $ | 45,362 | ||||
| Reconciliation of adjusted net earnings | ||||||||
| GAAP net earnings | $ | 28,986 | $ | 22,710 | ||||
| Inventory valuation adjustment (1) | — | 1,202 | ||||||
| Amortization of intangible assets and finance lease (2) | 6,474 | 7,422 | ||||||
| Transaction and integration costs (3) | 440 | 2,165 | ||||||
| Income tax adjustment (5) | (2,316 | ) | (2,918 | ) | ||||
| Adjusted net earnings | $ | 33,584 | $ | 30,581 | ||||
| Adjusted net earnings per common share - diluted | $ | 1.03 | $ | 0.94 | ||||
Table 2
(unaudited)
Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA
(Dollars in thousands)
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Net earnings - as reported | $ | 28,986 | $ | 22,710 | ||
| Add back: | ||||||
| Provision for income taxes | 7,864 | 6,409 | ||||
| Interest and other expenses | 4,826 | 5,289 | ||||
| Depreciation and amortization | 13,597 | 13,575 | ||||
| EBITDA | 55,273 | 47,983 | ||||
| Add back certain items: | ||||||
| Non-cash compensation expense related to equity awards | 4,750 | 4,770 | ||||
| Inventory valuation adjustment (1) | — | 1,202 | ||||
| Transaction and integration costs (3) | 440 | 2,165 | ||||
| Nonqualified deferred compensation plan expense (4) | 403 | 237 | ||||
| Adjusted EBITDA | $ | 60,866 | $ | 56,357 | ||
Table 3
(unaudited)
Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate
(Dollars in thousands)
| Three Months Ended March 31, | ||||||||||||
| 2024 | Effective Tax Rate | 2023 | Effective Tax Rate | |||||||||
| GAAP Income Tax Expense | $ | 7,864 | 21.3 | % | $ | 6,409 | 22.0 | % | ||||
| Impact of ASU 2016-09 (6) | 708 | 396 | ||||||||||
| Adjusted Income Tax Expense | $ | 8,572 | 23.3 | % | $ | 6,805 | 23.4 | % | ||||
Table 4
(unaudited)
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
(Dollars in thousands)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net cash provided by operating activities | $ | 33,388 | $ | 34,838 | ||||
| Capital expenditures and proceeds from the sale of assets | (6,573 | ) | (9,612 | ) | ||||
| Free cash flow | $ | 26,815 | $ | 25,226 | ||||
| (1) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company's cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business. |
| (2) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance lease consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, an intangible asset in connection with a company-wide ERP system implementation, and one finance lease. We record expense relating to the amortization of these intangibles and finance lease in our GAAP financial statements. Amortization expenses for our intangible assets and finance lease are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. |
| (3) Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (4) Nonqualified deferred compensation plan (income) expense: Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other (income) expense while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. Adjustments have been made to the prior period presentation to conform with the current period presentation. |
| (5) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. |
| (6) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three months ended March 31, 2024 and 2023, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. |
FAQ
What were Balchem 's net sales for the first quarter of 2024?
Balchem reported net sales of $239.7 million for the first quarter of 2024.
What was the adjusted EBITDA for Balchem in the first quarter of 2024?
Balchem achieved adjusted EBITDA of $60.9 million in the first quarter of 2024.
Which segment of Balchem saw a significant increase in sales and earnings in the first quarter of 2024?
The Human Nutrition & Health segment of Balchem recorded all-time high sales of $152.7 million, with earnings up 80.4% compared to the prior year.
What sustainability goals did Balchem highlight in their 2023 Sustainability Report?
Balchem highlighted goals to reduce greenhouse gas emissions and water usage by 25% by 2030 in their 2023 Sustainability Report.
What financial challenges did Balchem face in the Animal Nutrition & Health segment in the first quarter of 2024?
Balchem experienced a decrease in sales and earnings from operations in the Animal Nutrition & Health segment in the first quarter of 2024.
